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Abstract: We sought to characterize the lipid profile of skeletal muscle cell-derived Extracellular
Vesicles (EVs) to determine if a hypertrophic stimulus would affect the lipid composition of C2C12
myotube-derived EVs. Analyses included C2C12 murine myoblasts differentiated into myotubes
and treated with Insulin-Like Growth Factor 1 (IGF-1) for 24 h to induce hypertrophic growth.
EVs were isolated from cell culture media, quantified using Nanoparticle Tracking Analysis (NTA)
and analyzed using Transmission Electron Microscopy (TEM). EVs were homogenized and lipids
extracted for quantification by Mass Spectrometry followed by downstream lipid class enrichment
and lipid chain analysis. IGF-1 treatment elicited an increase in CD63 and CD81 levels (39% and 21%)
compared to the controls (16%), respectively. Analysis revealed that skeletal muscle-derived EVs
are enriched in bioactive lipids that are likely selectively incorporated into EVs during hypertrophic
growth. IGF-1 treatment of myotubes had a significant impact on the levels of diacylglycerol (DG)
and ceramide (Cer) in secreted EVs. Specifically, the proportion of unsaturated DG was two- to
three-fold higher in EVs derived from IGF-treated cells, as compared to those from control cells. The
levels of saturated DG were unaffected. Selective increases were similarly seen in C16- and C24-Cer
but not in other species. Levels of free sphingoid bases tended to decrease, while those of sphingosine-
1-phosphate was unaffected. Our results suggest that the lipid composition and biogenesis of skeletal
muscle-derived EVs, are specific and highly selective during hypertrophic growth.
Keywords: extracellular vesicles; lipids; muscle cell; muscle growth; EV biogenesis
1. Introduction
It is well accepted that virtually all cells are capable of secreting minute vesicles into the
extracellular space, a process that is conserved among bacteria, plants, and mammals [1–3].
These vesicles, collectively termed Extracellular Vesicles (EVs), can be categorized as either
exosomes, microvesicles, or apoptotic bodies, depending on their size and biogenesis
process [4]. The interest in EVs have grown exponentially following seminal work demon-
strating that EVs can transfer functional cargo to recipient cells [5,6]. As the field evolves,
the potential to utilize EVs as therapeutic delivery systems for drugs [7] and as biomarkers
for physiological and pathological conditions [8] is becoming clear. In addition, understand-
ing how EVs mediate effects on recipient cells provides a new means for intra/intercellular
crosstalk.
It is generally perceived that EVs arise from specific pathways depending on their
subtype [9,10]. For example, microvesicles are thought to shed off from the plasma mem-
brane from cytoplasmic protrusions [11], while exosomes are formed from invaginations of
endosomes, which give rise to intraluminal bodies/multivesicular bodies that fuse with the
plasma membrane and are released into the extracellular space [12]. While the EV subtype
nomenclature based on these mechanisms are well accepted, it has been argued that a
subtype of exosomes could bud directly from the plasma membrane [13,14], suggesting that
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there may be non-canonical pathways of EV biogenesis. These alternative pathways might
be dependent on a cellular type or perturbations. For example, in skeletal muscle cells,
it has been demonstrated that RNA localization varies depending on the developmental
stage of C2C12 myotubes and protein synthesis [15]. This exciting study indicates specific
hubs for cellular processes and supports the notion that events in the cell do not take place
randomly; hence, specific spatial locations serve a discrete purpose. These results might
suggest that the cells engage in a particular pathway of EV biogenesis upon receiving a
specific stimulus.
EVs are generally thought to contain biologically active cargo, such as mRNAs, miR-
NAs, proteins, and lipids, which mediate various effects on recipient cells [16]. A major
focus in EV research has been identifying the miRNA content carried within EVs (ex-
omiRs) [9,17,18]. Several studies have demonstrated that exomiRs are delivered to other
cells, where they regulate their cognate target genes usually at the posttranscriptional
level [19–22]. While these studies clearly demonstrated the functional transfer of miRNA,
some studies have suggested that the modulation of gene expression in target cells via ex-
omiRs may not account for all the biological properties of EVs [23]. For example, Chevillet
and co-workers quantified the number of miRNAs from plasma, seminal fluid, dendritic
cells, mast cells, and ovarian cancer cells and determined that there was less than one copy
of a given miRNA per EV [24]. Helwa and co-workers further demonstrated the abun-
dance of miRNA in EVs to be roughly one to two molecules of miRNA/EV [25]. This low
abundance theory raises questions regarding the ability of exomiRs to alter the function of
the recipient cells, since it was demonstrated that the typical concentration of a microRNA
per cell, to effectively induce target silence, is estimated to be around 1000 copies [26].
Although this mechanism could be a cell-type and/or physiological/pathological status
specific, it is interesting to speculate that there might be synergism among EV cargo to
induce a biological effect into a recipient cell. Therefore, a better understanding of the
various cargo within EVs could provide new information regarding their biological impact.
While exomiRs and proteins have been widely investigated, only recently has the
lipid signature of EVs gained attention. Lipids are the most abundant component of the
EV membrane bilayer, and it has been demonstrated that EVs are enriched for structural
lipids, such as sphingomyelin, hexosylceramide, phosphatidylinositol, and free choles-
terol [27–29]. In addition, lipids participate in EV biogenesis through various mechanisms,
such as forming lipid rafts that concentrate or select cargo, altering membrane curvature, fa-
cilitating pitching from the multivesicular bodies, and participating in ESCRT-independent
EV formation [30–33]. Furthermore, the lipids contained within EVs could be used as
biomarkers for pathologies and/or to track their progression from their own respective
biogenic pathway to the target cell(s) [34,35]. Specifically, EVs have been shown to contain
bioactive lipids, such as ceramide (Cer) and diacylglyceride (DG) [27,36], which have been
shown to be important for vesicular biogenesis, trafficking, and secretion [32,37–40]. These
bioactive lipids may also play a role in the regulation of signaling pathways on the recipient
cell, providing a possible mechanism of cell-to-cell crosstalk. Therefore, the lipid composi-
tion of EVs represents a new area of research not only for their role in EV biogenesis but
also for their biological effect on the target cell(s) [31,41,42]. Most of the studies addressing
exosome lipid content have been focused on structural lipids and show an enrichment from
cells to exosomes of 2–3 times for cholesterol, sphingomyelin (SM), glycosphingolipids,
and phosphatidylserine (PS), in a cell type-dependent manner. However, the levels of
lipid metabolites with bioactive properties, such as DG, Cer, and sphingosine-1-phosphate
(S1P), as far as one could ascertain, have not been investigated. A better understanding of
whether EVs contain bioactive lipid metabolites, and if so what determine this content, is
crucial for ultimately identifying the mechanism(s) by which these vesicles are formed and
participate in intercellular communication.
Skeletal muscle accounts for roughly 40% of total body mass and is known to secrete
a diverse spectrum of factors, collectively termed myokines, that participate in inter/intra
cellular communication [43–45]. Moreover, skeletal muscle has been shown to release EVs
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carrying muscle-enriched miRNAs that can regulate skeletal muscle plasticity as well as
recipient cells [46–51]. As noted previously, lipids may play a fundamental role in EV
biology; however, data regarding lipids in skeletal muscle-derived EVs is lacking. We
recently published data showing that skeletal muscle-derived EVs are secreted during
muscle hypertrophy which subsequently target adipose tissue, resulting in an increase in
lipolysis [22]. This is not seen under resting conditions, suggesting that during skeletal
muscle hypertrophy, a subset of EVs is secreted, influencing the biological function of
the recipient cell. One possible way to modulate the compositional features of EVs is to
regulate the lipid composition incorporated into the membrane. Therefore, the purpose
of this study was to characterize the lipid profile of skeletal muscle cell-derived EVs to
determine if a hypertrophic stimulus would affect EV biogenesis. We hypothesized that a
hypertrophic stimulus would affect the lipid composition of EVs compared to the control.
2. Materials and Methods
2.1. Cell Culture
The skeletal muscle cell line C2C12 (murine cell line from American Type Culture
Collection, ATCC) myoblasts were grown in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 10% fetal bovine serum, 100 units/mL of penicillin, and 100 µg/mL of
streptomycin at low confluence. To induce differentiation, growth medium was switched
to DMEM supplemented with 2% horse serum, 100 units/mL of penicillin, and 100 µg/mL
of streptomycin when cells were fully confluent. In order to remove contaminating my-
oblasts from the myotube cultures, differentiated myotubes were treated with 10 µm
arabinosylcytosine (AraC; Sigma, St. Louis, MO, USA) for 24 h. Following treatment with
AraC, cells were washed in phosphate-buffered saline (1X PBS) and transferred back into
differentiation media for a 24 h recovery period prior to further treatments.
2.2. IGF-1 Treatment
Following 7 days of differentiation [52], C2C12 myotubes were treated with either PBS
(Control) or recombinant IGF-1 (Treated, 200 ng/mL in serum/antibiotic-free media) for
24 h. After 24 h, the media were collected for EV isolation. This series of experiments were
performed in 3 independent T150 cell culture flasks.
2.3. Extracellular Vesicle Isolation
EVs were isolated using Cushioned-Density Gradient Ultracentrifugation (C-DGU
G) [53,54]. Briefly, ~40 mL of the serum/antibiotic-free media was centrifuged at 3000× g
for 15 min to eliminate cell debris, followed by filtration (0.22 µm). The filtered media
were added to a liquid cushion (60% Iodixanol) and ultracentrifuged at 150,000× g for
4 h at 4 ◦C to concentrate the small vesicles. Subsequently, these vesicles were resolved
in a density gradient (40, 20, 10, and 5% iodixanol) and submitted to ultracentrifugation
at 100,000× g for 18 h at 4 ◦C. The EV-rich, protein-low fractions (6 and 7) were then
pooled and concentrated to 500 µL on an Amicon Ultra-4 Centrifugal Filter Unit with an
Ultracel-10 membrane (MWCO = 10 kDa; Merck Millipore, Darmstadt, Germany, United
States Affiliate) by centrifugation at 4000× g for 30 min.
2.4. Nanoparticle Tracking Analysis (NTA)
EV concentration and size distribution were determined using a NanoSight NS300
(Malvern Instruments Ltd., Worcestershire, UK) equipped with a 488 nm blue laser and a
CMOS camera that allows for detection and quantification of small particles (~50–1000 nm).
As the particles move via Brownian motion, their speed is relative to their size, which can
be estimated by the Stokes–Einstein equation [55]. EV samples were diluted (1:1000) in
Dulbecco’s phosphate-buffered saline (DPBS). Samples were captured at room temperature
with automatic temperature monitoring. Each sample was captured 5 times at 60 s intervals
(camera level 11). The resulting videos were analyzed with NTA software version 3.0
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(detection threshold 5) where the mean values for concentration and size distribution were
calculated.
2.5. Transmission Electron Microscopy (TEM)
A 30 µL droplet of purified EVs was placed on parafilm and the surface of a carbon-
formvar-coated copper grid was placed upside down to make contact with the samples
(~2 min). Afterward, the excess specimen was wicked away by touching a piece of filter
paper to the edge of the grid surface, followed by 30 s of air drying. The grid was placed
upside down onto a droplet of stained solution (1% phosphotungstic acid) for ~2 min.
Excess fluid was wicked from the grid following staining, leaving a thin aqueous film on
the surface, which was allowed to air dry. Samples were examined at 80 kV under a Hitachi
H7500 TEM [56,57].
2.6. EV Detection with Exo-Check™ Antibody Array
A membrane-based antibody array (Exo-Check™, System Biosciences, Palo Alto, CA,
USA) was used to detect 8 known EV markers (FLOT-1, ICAM1, ALIX, CD81, CD63, Ep-
CAM, ANXA5, and TSG101), a GM130 cis-Golgi marker (cellular contamination control), a
labeled positive control for HRP detection, and a blank spot as a background control, fol-
lowing the manufacturer’s instructions. First, the EV protein concentration was measured
by a Qubit Protein assay kit (ThermoFisher, Waltham, MA, USA), using a Qubit Fluorome-
ter 3.0 (ThermoFisher, Waltham, MA, USA). Next, 10 µg of pooled EV protein was lysed
and incubated overnight in the antibody membrane array. Following the washing steps,
the membrane was incubated with a detection buffer (Detection Reagent A + Detection
Reagent B) and chemiluminescence was measured using a ChemiDoc MP System (Bio-Rad
Laboratories). Band intensities were calculated with molecular imaging software (Image
Lab, Bio-Rad Laboratories).
2.7. Lipid Extraction and Analyses
The lipid profile of whole myotube cells (n = 3/group) and their corresponding EVs
(n = 3/group) were analyzed at the Lipidomics Core of the Medical University of South
Carolina on a Thermo Fisher TSQ Quantum triple quadrupole mass spectrometer, operating
in a multiple reaction monitoring positive ionization mode, as previously described [58].
Briefly, all EVs recovered from the same number of cells and the myotube cells were
homogenized and aliquots of the homogenates equivalent to 1.5 mg of protein were
injected with the appropriate internal standards (ISs). Lipids were extracted twice with
a 2 mL ethyl acetate, isopropanol, and water (60:30:10 v/v/v) solvent. Lipid extracts were
evaporated and reconstituted in 150 µL of 1 mM ammonium formate in 0.2% formic acid
in methanol before being subjected to Liquid Chromatography–Mass Spectrometry (LC-
MS/MS) on an HP1100/TSQ Quantum LC-MS/MS system. Samples were gradient-eluted
from the BDS Hypersil C8, 150 mm × 3.2 mm, 3 µm particle size column, with a 1.0 mM
methanolic ammonium formate per 2 mM aqueous ammonium formate mobile phase
system. Peaks corresponding to the target analytes and ISs were collected and processed
using the Xcalibur software system. Quantitative analysis was based on the calibration
curves generated by spiking of an artificial matrix with the known amounts of the target
analyte synthetic standards and an equal amount of the ISs. The target analyte/IS peak
area ratios were plotted against the analyte concentration. The target analyte/IS peak area
ratios from the samples were similarly normalized to their respective IS and compared
with the calibration curves using a linear regression model. The results from this linear
regression model were analyzed using lipidR software [59]. Briefly, lipid name parsing
was performed to generate the lipid classes, chain lengths, and numbers of unsaturated
bonds based on the LIPID MAPS Structure Database [60]. Following quality control,
normalization was performed using probabilistic quotient normalization [61], followed
by statistical analysis employing a linear model fit and calculating a moderated t statistic
to identify the significantly different lipids between groups (control and IGF-treated) [62].
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Differentially expressed genes were estimated using the empirical Bayes function with a
false discovery rate (FDR) of 5%, using the Benjamini–Hochberg method.
2.8. Lipid Class Enrichment and Lipid Chain Analyses
A lipid set enrichment analysis was performed in the top lipids, based on fold-change,
to detect preferential regulation of lipid classes, total chain lengths, or total unsaturation
patterns between groups.
2.9. Statistical Analyses
All data are presented as the mean ± SE. Except for lipidomic data (statistical analyses
discussed above), after determining normal distribution of the data using a Shapiro–Wilk
test, a two-sided Student’s t-test was performed to test the effect of IGF-1 treatment on cells
and EVs. Statistical analysis was performed with GraphPad Prism version 9.2.0 (GraphPad
Software, San Diego, CA, USA). Statistical significance was set at p < 0.050.
3. Results
3.1. EV Characterization between IGF Treatment and Control
To determine if a hypertrophic stimulus (IGF-1 treatment) would impact EV biogen-
esis and release, we harvested EVs from the media of both the control and IGF-treated
skeletal muscle cells and performed EV characterization. IGF treatment resulted in slightly
lower levels of EV concentration compared to the control (Figure 1A). Additionally, there
was no difference in size between the control and IGF-treated myotube-derived EVs
(104.2 nm ± 1.10 nm and 102.13 nm ± 2.48 nm) (Figure 1B). The EV isolation procedures
employed in this study resulted in a homogeneous population of EVs (characteristics
similar to exosomes), as shown by TEM (Figure 1C), with specific EV surface markers
and no cellular contamination (Figure 1D). Interestingly, the IGF-treated myotube-derived
EVs were comprised of different levels of tetraspanin compared to the control (Figure 1E).
Specifically, we found that EVs from the IGF-treated myotubes presented a substantial
increase in CD63 levels compared to control EVs (39.3% vs. 6.4%, respectively). In ad-
dition, we observed that the most abundant protein markers found in the control EVs
were ALIX (25%), followed by TSG101 (17%), ICAM, and CD81 (16%); whereas, in the
IGF-treated myotube-derived EVs, CD63 was the most abundant, followed by CD81 (21%)
and ALIX (8%).
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Figure 1. Characterization of myotube-derived EVs: (A)—myotube-derived EV control (control) and IGF-treated myotube-
derived EV (IGF) concentration; (B)—EV size between the control and IGF; (C)—representative TEM image of the myotube-
derived EVs, scale size 200 nm; (D)—EV marker protein concentration between the control and IGF; (E)—pie chart
representing the percent of each EV protein markers in the control and IGF. (A,B) Data are presented as the mean ± SE
(n = 3).
3.2. Comparison of the Lipid Profiles between Myotubes and Myotube-Derived EVs
To test whether myotube-derived EVs contain bioactive lipids and how their bioactive
lipid content compares to that of the donor cells, mass spectrometry-based analyses of
the EVs and myotubes were performed. Specifically, with respect to SM, Cer, DG, and
free (sphingosine (Sph) and dihydrosphingosine (dhSph)) and phosphorylated (S1P and
dihydrosphingosine-1-phosphate (dhS1P)) sphingoid bases, as well as their respective
phosphorylated bases (Figure 2A–D), were analyzed. As compared to myotubes, EVs were
enriched in Di-C16-DG, as well as in DG containing arachidonic acid (C20:4), a product
of Phospholipase C activation in the cells (Figure 2A). Ceramides containing C16 and
C22:1 fatty acid were the major species in EVs, while in myotubes different Cer species,
namely, C24:1 and C24:0, were most abundant (Figure 2B). As anticipated, SM is very
abundant in EVs and the profile of SM species (i.e., length and saturation of the fatty acid
attached to the C18:1 sphingoid base) was similar for the myotubes and EVs (Figure 2C).
In both cases, C16 was by far the most abundant SM species, accounting for 60% of
all sphingomyelins of the total SM content, followed by C24:1 (Figure 2C). The relative
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abundance of the free sphingoid bases (C18:0, sphinganine, and C18:1, sphingosine) as well
as their phosphorylated forms, sphingosine-1-phosphate and sphinganine-1 phosphate,
was similar for the myotubes and EVs (Figure 2D). Together, these results illustrate that
(i) myotube-derived EVs carry a significant amount of bioactive lipids; and (ii) these
bioactive lipids are most likely incorporated into the EVs through a process with some
degree of selectivity, as they do not simply reflect the content of the cellular membranes of
the donor cells.
Figure 2. Lipid composition of the myotubes and their secreted EVs: (A)—diacylglycerol; (B)—sphingomyelin; (C)—
ceramide; and (D)—free and phosphorylated sphingoid bases. Data are presented as percent enrichment in specific species
(n = 3).
3.3. Changes in Bioactive Lipid Profiles of EVs Following IGF Treatment of Myotubes
Having determined that EVs contain bioactive lipids, we then sought to test if this
composition varies in different physiological conditions. The lipid profile from the con-
trol and IGF-treated myotubes and their corresponding EVs were analyzed by targeted
LC-MS/MS. Unsupervised clustering analyses by principal component analysis (PCA) re-
vealed similar patterns of the lipid composition between groups in myotubes. Interestingly,
we observed a distinct cluster in myotube-derived EVs, represented by PC1 explaining
55.1% and PC2 explaining 20.1% of the variability, suggesting differences in lipid composi-
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tion between groups (Figure 3A,B). Confirming our clustering analysis, we observed no
statistical difference between the control and IGF-treated myotubes for DG (Figure S1), SM
(Figure S2), and Cer (Figure S3). Despite no changes in the lipid profile of the myotubes,
there was a distinct and significant different lipid profile in the EVs between each respective
group (Figure 3C). Specifically, the IGF-1 treatment stimulated the release of EVs with
higher levels of Cer (d18:0/16:0, d18:1/18:1, d18:1/20:1), DG (C16:1/18:0, C16:1/16:1),
glucosylceramide (GlcCer, d18:1/22:1), Sulfatides Hexosyl ceramides (SHexCer, 18:1/18:0),
and Sphingosine-1-phosphate (SPBP, 18:1), and lower levels of SM (d18:1/20:0, d18:1/22:0)
and GlcCer (d18:1/24:0). Complementarily, our lipidomic analysis revealed a significant
(adjusted p-value < 0.050) increase in unsaturation at position 2 of the carbon chains in the
IGF-treated group compared to the control group (Figure 3D). Increasing the amount of
unsaturated lipids in the membranes has been shown to increase their fluidity [63] and mit-
igates the unfolded protein response [64]. Therefore, adjusting the degree of unsaturation
could be a way to increase the half-life and stabilization of the EVs before secretion.
Figure 3. EV lipid profile characterization. Principal component analysis (PCA) plot between the control and IGF in
myotubes (A) and myotube-derived EVs (B); (C)—volcano plot highlighting the significant lipid differences between the
control and IGF EV; (D)—lipid chain plot revealing an increase in the degree of carbon chain saturation between the control
and IGF EVs. (C,D) Data are represented as fold change in the IGF-treated myotube-derived EVs compared to the control.
Significance is denoted (red) with an adjusted p-value < 0.05 (n = 3).
3.4. IGF Treatment Exerts a Specific Impact on EV Lipid Composition
Since we did not observe significant differences in the lipid profile of myotubes, the
following analyses were focused on myotube-derived EVs. To assess the impact of IGF-1
treatment on the lipid profiles of EVs, the levels of individual lipid species were normalized
for the amount of lipid-associated phosphate (a measure of total phospholipids in each
preparation). Such normalization allowed us to discern changes that are specific for particu-
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lar lipid classes from any changes that might be the result of an overall increase/decrease in
total lipid content. These revealed that following IGF-1 treatment, the content of DG in the
EVs increased by approximately 30% (Figure 4A). However, these increases were attributed
to only a few specific species. Notably, dipalmitoyl-sn-glycerol (Di-C:16), which is the
major DG species present in EVs, were not affected by IGF-1 treatment. Another major
DG species containing saturated fatty acids only, stearoyl-palmitoyl-sn-glycerol (C:14-
C:16), was similarly unaffected. However, the abundance of DG containing unsaturated
fatty acids substantially increased following IGF treatment and the levels of C16:0-C18:1,
C16:1-C18:0, C16:1-C18:1, C18:0–20:4, and Di-C16:1-DG doubled in the EVs derived from
IGF-treated myotubes. Noteworthy, the C18:0-C20:4 levels tripled, demonstrating that IGF
treatment had a greater effect on this particular DG species. (Figure 4B,C). Together, these
data indicate that the IGF treatment of myotubes has a specific effect on the DG content of
EVs, causing an increased abundance of DG with unsaturated fatty acids. The presence of
selective changes also implies the involvement of lipid-metabolizing enzymes of distinct
substrate specificity in the apparent remodeling of the DG content of EVs in response to
hypertrophic conditions.
Figure 4. Effect of IGF-1 treatment on the diacylglycerol (DG) composition of myotube-derived
EVs: (A)—pie chart highlighting the DG species in myotube-derived EV control and IGF-treated
myotube-derived EVs; (B)—DG species normalized for the amount of lipid-associated phosphate (a
measure of total phospholipids in each preparation); (C)—unsaturated, saturated, and total DG in
control and IGF EVs. Data are presented in percentage (A) and as the mean ± SE (B,C) (n = 3), with
significance denoted by an asterisk compared to the control.
We then analyzed the composition of SM, a structural lipid (Figure 5A). We observed
a significant (adjusted p-value < 0.050) increase in C16 and C18:1 species in the IGF-
treated myotube-derived EVs compared to control EVs. Furthermore, we found that IGF-1
treatment caused a significant reduction in C20 and C22 species compared to the control
(Figure 5B). The length/saturation of the acyl chain in SM could contribute to the overall
structure and/or function of EVs, by affecting the fluidity and stability of the lipid bilayer,
as well as the affinity/strength of the interaction between SM and cholesterol. These
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results suggest another degree of selectivity in the generation of EVs during skeletal muscle
growth.
Figure 5. Effect of IGF-1 treatment on the sphingomyelin (SM) composition of myotube-derived
EVs: (A)—pie chart highlighting the SM species in EVs derived from the control and IGF-treated
myotubes; (B)—SM species normalized for the amount of lipid-associated phosphate (a measure of
total phospholipids in each preparation). Data are presented in percentage (A) and as the mean ± SE
(B) (n = 3), with significance denoted by an asterisk compared to the control.
Similarly, we observed species-specific differences between the IGF-treated myotube-
derived EVs and control EVs with regards to Cer (Figure 6A). The major species of Cer,
namely, C16-, C24:1-, and C24:0-Cer, more than doubled following IGF treatment, while
the minor species were unaffected. Interestingly, Cer can be produced by two metabolically
distinct pathways, via hydrolysis of SM (mediated by sphingomyelinases, including neutral
sphnogmyelianse-2, which is necessary for exosome secretion) or by the de novo pathway
(mediated by Serine-Palmitoyltransferase and Cer synthases). Notwithstanding, the levels
of dihydroceramide (DH-Cer) (Figure 6C), which is a precursor in the latter pathway,
similarly increased, indicating possible involvement of de novo synthesis in the IGF-1-
induced increase in EV Cer content. Furthermore, IGF-treated myotube-derived EVs had
significantly (p-value < 0.050) less free sphingoid bases, particularly sphingosine, when
compared to control EVs (Figure 6D). Taken together, these results suggest that skeletal
muscle cell-derived EVs carry a significant amount of bioactive lipid metabolites and the
fatty acid make-up of these bioactive lipids is strongly affected in conditions of muscle
hypertrophy. Structural details in the DG and Cer molecules, including the length and
saturation of the fatty acid, are not only introduced via distinct metabolic pathways, but
also determine to a large extent the bioactive properties of these molecules. Therefore, our
results provide strong evidence that the lipid content of the EVs released by a normal and
hypertrophic muscle differ and may have a different impact on target cells.
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Figure 6. Effect of IGF-1 treatment on the ceramide (Cer) composition of myotube-derived EVs:
(A)—pie chart highlighting the Cer species in EVs derived from the control and IGF-treated my-
otubes; (B)—Cer species normalized for the amount of lipid-associated phosphate (a measure of total
phospholipids in each preparation). Total amount of dihydro-ceramide (DH) (C) and sphingoid bases
(D) between the control and IGF EVs. dhSph: dihydrosphingosine; dhSph-1P: dihydrosphingosine-
phosphate; Sph: sphingosine; Sph-1P: sphingosine-phosphate. Data are presented in percentage (A)
and as the mean ± SE (B–D) (n = 3), with significance denoted by an asterisk compared to the control.
4. Discussion
This study has provided evidence that a hypertrophic stimulus modulates EV biogen-
esis in skeletal muscle cells. Furthermore, by utilizing a robust method of EV isolation that
yields a more homogeneous population (enrichment of exosomes), we demonstrated, for
the first time, that myotube-derived EVs are enriched with specific bioactive lipids com-
pared to that of the donor cells. Interestingly, our results demonstrate that the hypertrophic
stimulus elicited by IGF-1 treatment alters the EV’s lipid composition, while having little
effect on the composition of the donor cells. Specifically, IGF-treated myotube-derived
EVs contained a substantial amount of unsaturated DG species compared to control EVs.
Additionally, the EVs from the IGF-treated myotubes demonstrated specific increases in SM
and Cer species, notably C16/C18 SM and C16 Cer. Interestingly, there was less sphingoid
bases in the EVs from the IGF-treated myotubes, suggesting that Cer is preferentially
incorporated into EVs over other sphingolipids. Skeletal muscle cell growth altered the EV
marker proteins (i.e., CD63 and CD81), suggesting a different membrane composition is
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present in said EVs. Together, our results indicate that during skeletal muscle cell hypertro-
phy, exosome biogenesis could occur via a non-canonical pathway, possibly demonstrating
that skeletal muscle cells have the capacity to utilize different pathways of EV biogenesis
under the influence of specific stimuli (Figure 7).
Figure 7. Proposed model of EV biogenesis in C2C12 myotube cells in resting conditions (A) and
during muscle growth (B). In resting conditions, microvesicles and exosomes are formed through a
canonical EV biogenesis mechanism, whereas during muscle growth an additional non-canonical
exosome biogenesis mechanism might take place at the plasma membrane.
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Currently, the mechanisms associated with biogenesis aid in the classification of EV
subtypes. For example, the most studied EV subtypes to date, microvesicles (ectosomes)
and exosomes, are classified according to their biogenic processes. Specifically, microvesi-
cles (ectosomes) are formed by budding off of the plasma membrane, while exosomes
have been classically described as an ‘endosome-only’ mechanism [9,13,65]. However,
recent research has suggested that exosome biogenesis may occur via a non-canonical
pathway taking place at the plasma membrane [13]. In this elegant study, Gould’s group
demonstrated that redirecting CD63 from endosomes to the plasma membrane increased
its exosomal secretion 6-fold, whereas redirecting CD9 to endosomes reduced its exosomal
secretion 5-fold [13]. The authors concluded that there is a common pathway that exosomes
utilize for their biogenic process that occurs at both plasma and endosome membranes.
A similar study conducted by Théry’s group made comparable observations; however,
this group classified these vesicles as small ectosomes, since they were formed at the level
of the plasma membrane [66]. Regardless of the nomenclature used, it is clear that EVs
with similar characteristics of exosomes (size and classical markers) are formed at the
plasma membrane. In addition, EV release fluctuates by utilizing different pathways, thus
illustrating that the secretion of EVs is specific when comparing biogenesis and/or release
from one compartment over the other.
Similar to these studies, we observed an enrichment in membrane-associated proteins
in the IGF-treated myotube-derived EVs compared to control EVs. Specifically, our results
demonstrate a substantial increase in CD63 and a slight increase in CD81 levels following
IGF-1 treatment. Additionally, we detected a significant decrease in the amount of EVs
secreted using a hypertrophic stimulus. Although limited, these results suggest that during
skeletal muscle growth, a distinct EV population is preferentially formed and released.
Even though isolation of a single population of EVs is challenging, in our study, the
isolation method resulted in a homogeneous population of EVs (size and morphology)
with similar characteristics of exosomes rather than a consortium of vesicles. Therefore,
we propose that myotubes, under a hypertrophic stimulus, preferentially produce EVs
(most likely exosomes) at the plasma membrane. While additional experiments are needed
to confirm/refute these findings, this possibility presents exciting new areas for skeletal
muscle EV research.
Aside from tetraspanin differences, which may suggest spatial differences in EV
biogenesis, our lipidomic analysis highlights EV heterogeneity between the IGF-treated
myotube-derived EVs and control EVs. Lipids are among the most abundant molecules
within EVs with essential roles in structure (membrane stability and rigidity), formation,
and release, and are potent modulators of cell signaling. Interestingly, the lipid incorpora-
tion in EV membranes seems to be a highly selective mechanism, as the lipid composition
does not mirror the membrane composition of the donor cell(s). In fact, differences in lipid
composition between EVs and the respective donor cells have been previously demon-
strated [27,67]. Comparable to these studies, our results also demonstrate a specificity
in EV lipid composition with an enrichment of SM and Cer in EVs when compared to
myotubes. While both lipid species have been shown to participate in EV biogenesis and
membrane organization [68,69], their roles in EV biology are not fully characterized.
Despite the differences between EVs and muscle cells, we did not observe any dif-
ference in the lipid composition in myotubes between groups. Curiously, our results
suggest that a hypertrophic stimulus induces a distinct lipid profile in the EVs derived
from growing myotubes. Differences in the lipid profiles of EVs have already been identi-
fied between cancer and non-cancerous cells [70], indicating that EV biogenesis is not static
but rather a dynamic mechanism that is cell type/perturbation dependent. One of the most
striking changes observed in our study was the significant enrichment of DG. Specifically,
the levels of unsaturated C16:0-C18:1, C16:1-C18:0, C18:1-C16:1, and Di-C16:1 doubled,
while C16:0-C20:4 nearly tripled in the IGF-treated myotube-derived EVs compared to
control EVs (Figure 3A–C). DG is present in the plasma membrane and is considered a
bioactive lipid, representing a major secondary messenger in addition to contributing to
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membrane curvature and fusion [71]. Consequently, the incorporation of DG into the EVs
from IGF-treated myotubes may provide these vesicles with certain characteristics that
enable them to target specific recipient cells. The increases seen in palmitoyl-arachidonoyl
(C16:0-C20:4)-sn-gycerol is particularly interesting because, on one hand, this type of DG is
produced selectively via activation of Phospholipase C, while, on the other hand, it contains
the lipid precursor for the synthesis of prostaglandins and leukotrienes (arachidonic acid).
Additionally, the packaging of DG in EVs under a hypertrophic stimulus could be a means
by which skeletal muscle enables itself to become more insulin sensitive. DGs can induce
insulin resistance in skeletal muscle by activating PCK-θ, impairing the insulin receptor
substrates’ ability to activate PI3 kinase [72]. In support of this idea, it has been shown
that DG species are highly correlated with insulin resistance and significantly lower in
athletes [73]. Therefore, the release of DG via EV secretion after a hypertrophic stimulus
could allow muscle cells to become transiently more inulin sensitive, resulting in higher
glucose uptake. Alternatively, myotube-derived EVs carrying high amounts of DG to the
target tissues may transiently decrease the insulin sensitivity in the recipient cells, allowing
skeletal muscle to consume the majority of the circulating glucose. Although possible, the
exact mechanism of DG in EV biology requires further investigation. Regardless, our re-
sults demonstrated that under a hypertrophic stimulus, specific DG species become highly
enriched in EVs, therefore suggesting a specific function during skeletal muscle growth.
In addition to increases in specific DG species, we report that C16-, C24:1- Cer, and
dihydroceramide are significantly elevated in EVs from IGF-treated myotubes. Ceramides
are precursors to sphingolipids, produced from a four-step cascade that begins with the
condensation of serine and palmitoyl-CoA [74]. Previously, it was found that Cer plays a
role in EV biogenesis by interacting with endosomes and lysosomes, initiating an ESCRT-
independent pathway [32,75] via nSMase2, which is essential for exosome biogenesis in
some cells [76]. We previously found that mice treated with an nSmase2 inhibitor (GW4869)
had a significant decrease in EV concentration [22]. Cer is also important for mediating
the EV response in the recipient cell, which suggests that this particular lipid adds to the
functionality of EVs. For example, EV-specific Cer can be incorporated into lipid rafts,
which has the potential to regulate the signaling cascades in a recipient cell [23]. It is
interesting to note that Cer in skeletal muscle, specifically C16, is associated with insulin
resistance [77] and impairs myogenic differentiation in C2C12 myotubes [78]. C16 Cer has
also been shown to specifically interact with P53 with its central DNA-binding domain,
promoting P53 stabilization [79]. These authors reported that the binding of C16 Cer
to P53 increased during starvation, demonstrating that C16 increases the pro-apoptotic
pathways during periods of stress [79]. Therefore, the release of C16 Cer in EVs from
muscle cells during hypertrophy could be the means by which muscle communicates
with other tissues to downregulate or alter their metabolism. Conceptually, this would
ensure that muscle consumes the appropriate amount of energy required for anabolism.
Furthermore, this idea is in agreement with our previous work, where we show that EVs
secreted by skeletal muscle during mechanical overload target adipose tissue, resulting in
an increase in lipolysis [22]. This could be a mechanism whereby growing skeletal muscle
signals to adipose tissue to increase the triacylglycerides that would support hypertrophic
growth. Future studies are warranted and will need to determine the importance of this
lipid in skeletal muscle cell-derived exosomes and their effect on systemic tissues.
The present study is not without its limitations. While our data provide specific
information on skeletal muscle cell-derived EVs, our in vitro model of hypertrophy only
indirectly reflects the mechanism(s) that are seen using various in vivo skeletal muscle
hypertrophy models. Additionally, while our isolation method should yield a more homo-
geneous population of EVs (mainly exosomes), we cannot discard the possibility that small
vesicles with the same density were co-isolated with our current population of EVs. Thus,
we have chosen to characterize our vesicles as EVs rather than a specific subtype. Finally,
we do not provide any downstream target cell-to-cell interaction analysis to determine the
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impact of skeletal muscle cell-derived EVs on the recipient cell and cannot conclude that
EVs from the control or IGF-treated myotubes specifically affect systemic tissues.
5. Conclusions
In conclusion, this study provides the first evidence that demonstrates that a hyper-
trophic stimulus affects the composition of lipids in EVs. In addition, we show that the
lipid composition differs between the parent cell and EVs, suggesting the lipid selectivity
of the EVs is highly regulated. We also present initial findings that suggest that under a
hypertrophic stimulus the biogenesis of EVs may preferentially occur at a different cellu-
lar location. The implications of these data could greatly improve the ability to identify
pathways for EV biogenesis and subsequently track EVs from skeletal muscle after exer-
cise. Finally, the lipid composition of myotube-derived EVs may provide information that
pertains to the function of these EVs in the recipient cell.
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Figure S1. Diacylglycerol (DG) composition of C2C12 myotube cells. A- Pie chart highlighting DG species between 
myotube control (control) and IGF-treated myotubes (Treated); B- DG species between groups normalized for the amount 
of lipid-associated phosphate (a measure of total phospholipids in each preparation); C- Unsaturated, saturated and total 
DG between control and treated cells. Data is presented as percentage (A) and as mean ± SE (B-C) (n=3) with significance 
denoted by an asterisk compared to Control. 
 




Figure S2. Sphingomyelin (SM) composition of C2C12 myotube cells. A- Pie chart highlighting SM species between 
myotube control (control) and IGF-treated myotubes (Treated); B- SM species between groups normalized for the amount 
of li-pid-associated phosphate (a measure of total phospholipids in each preparation). Data is presented as percentage (A) 
and as mean ± SE (B) (n=3) with significance denoted by an asterisk compared to Control. 




Figure S3. Ceramide (Cer) composition of C2C12 myotube cells. A- Pie chart highlighting Cer species between myotube 
control (control) and IGF-treated myotubes (Treated); B- Cer species between groups normalized for the amount of 
lipid-associated phosphate (a measure of total phospholipids in each preparation); Total amount of dihydro-ceramide 
(DH) (C) and sphingoid bases (D) between Control and Treated cells. dhSph: dihydrosphingosine, dhSph-1P: 
dihydrosphingosine-phosphate, Sph: sphingosine; Sph-1P: sphingosine-phosphate. Data is presented as percentage (A) 
and as mean ± SE (B-D) (n=3) with significance denoted by an asterisk compared to Control. 
 
